Compounds > erlotinib
Page last updated: 2024-09-05

erlotinib and su 4312

erlotinib has been researched along with su 4312 in 5 studies

Compound Research Comparison

Studies
(erlotinib)		Trials
(erlotinib)		Recent Studies (post-2010)
(erlotinib)		Studies
(su 4312)		Trials
(su 4312)		Recent Studies (post-2010) (su 4312)
221018033018

Protein Interaction Comparison

ProteinTaxonomyerlotinib (IC50)su 4312 (IC50)
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)4.4
Luciferin 4-monooxygenasePhotinus pyralis (common eastern firefly)4.45
Platelet-derived growth factor receptor betaHomo sapiens (human)3.7286
Vascular endothelial growth factor receptor 1Mus musculus (house mouse)0.8

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gangjee, A; Ihnat, MA; Kurup, S; Shenoy, SS; Thorpe, JE1
Disch, BC; Gangjee, A; Ihnat, MA; Raghavan, S; Zhao, Y1
Disch, B; Gangjee, A; Ihnat, MA; Kurup, S; Thorpe, JE1
Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y1
Bastian, A; Disch, BC; Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Zaware, N1

Other Studies

5 other study(ies) available for erlotinib and su 4312

ArticleYear
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
    Bioorganic & medicinal chemistry, 2010, May-15, Volume: 18, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Diamines; Indoles; Male; Melanoma; Mice; Mice, Nude; Molecular Structure; Phosphorylation; Pyrimidines; Pyrimidinones; Pyrroles; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2010
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
    Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14

    Topics: Angiogenesis Inhibitors; Cell Line, Tumor; ErbB Receptors; Humans; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Vascular Endothelial Growth Factor Receptor-2

2010
N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
    Bioorganic & medicinal chemistry, 2012, Jan-15, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Cell Line, Tumor; Diamines; Enzyme Activation; ErbB Receptors; Humans; Protein Kinase Inhibitors; Pyrimidines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2012
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
    Bioorganic & medicinal chemistry, 2012, Jul-15, Volume: 20, Issue:14

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta

2012
Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.
    Bioorganic & medicinal chemistry, 2013, Apr-01, Volume: 21, Issue:7

    Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Diamines; Halogenation; Humans; Indoles; Pyrimidines; Vascular Endothelial Growth Factor Receptor-2

2013